A Phase I Study of Autologous T Cells Transduced with Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients with Acute Myeloid Leukemia, Myelodysplastic Syndrome, and other Hematologic Malignancies
Dr. James Kochenderfer and team with the National Cancer Institute at the National Institutes of Health (NIH) are conducting a clinical research study evaluating an investigational immune cell (T-cell) therapy for adults with certain blood cancers that have not responded to standard treatments. Our goal is to see if this approach is safe for people with blood cancers.
Phase 1 Study with Dose Expansion of the Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants with Mesothelin-Expressing Solid Tumors Including Mesothelioma
Researchers at NCI are developing a new investigational treatment known as TNhYP218 CAR T cells to target and kill tumor cells in people with solid tumors and with those that have high levels of mesothelin (MSLN) including mesothelioma. The study team collects immune cells (T cells); the T cells are genetically modified to target and kill tumor cells to potentially shrink the tumor.
Evaluation for NCI Surgery Branch Clinical Research Protocols
Doctors at the National Cancer Institute (NCI) are looking for volunteers with metastatic cancers, including breast, ovarian, endometrial, gastrointestinal, genitourinary, hepatobiliary, pancreatic, melanoma, non-small cell lung cancer (NSCLC), and multiple myeloma with solid masses. Potential participants will be evaluated with new immunotherapy treatments utilizing cell transfer immunotherapies in a research trial.
